Lessons from TiNivo-2 and CONTACT-03
A panelist discusses how the CONTACT-03 and TiNivo-2 studies yielded important insights about ICI rechallenge and tivozanib in the post-ICI setting, with particular attention to the notable 9.2-month median PFS with tivozanib monotherapy, the impact of dosing strategies, and the timing of therapy initiation, though questions remain about the broader implications for ICI rechallenge efficacy across different treatment contexts.
Video content above is prompted by the following:
- What was learned from the CONTACT-03 and TiNivo-2 studies?
- What is your reaction to the efficacy data
- The combination arm?
- The tivozanib monotherapy arm?
- The 9.2-month median PFS of second-line tivo immediately following an ICI?
- Do you consider the results to be meaningful or practice changing?
- Please discuss the reduced dosage of tivozanib used in TiNivo-2 and the inclusion of patients with a ≤6 week break from immediate prior therapy in TiNivo-2?
- Please contrast that w/ design of CONTACT-03
- Do you agree that the results of the TiNivo-2 and CONTACT-03 studies clearly demonstrate that ICI rechallenge is not efficacious?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
